• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Development of Assay Methods to Measure Salmon Calcitonin with Highly Sensitivity : Determination of the Bioavailability of Nasal Salmon Calcitonin.

Research Project

Project/Area Number 06557136
Research Category

Grant-in-Aid for Developmental Scientific Research (B)

Allocation TypeSingle-year Grants
Research Field 医薬分子機能学
Research InstitutionSetsunan University

Principal Investigator

KOIDA Masao  Setsunan University Faculty of Pharmaceutical Sciences Professor, 薬学部, 教授 (80039651)

Co-Investigator(Kenkyū-buntansha) OHKUBO Satoru  Sandoz Pharmaceuticals, LTD.Tsukuba research center Research Scientist, 筑波総合研究所, 研究員
KOHNO Takeyuki  Setsunan University Faculty of Pharmaceutical Sciences Associate Professor, 薬学部, 講師 (50178224)
NAKAMUTA Hiromichi  Setsunan University Faculty of Pharmaceutical Sciences Assistant Professor, 薬学部, 助手 (70164275)
Project Period (FY) 1994 – 1995
Project Status Completed (Fiscal Year 1995)
Budget Amount *help
¥3,600,000 (Direct Cost: ¥3,600,000)
Fiscal Year 1995: ¥3,600,000 (Direct Cost: ¥3,600,000)
Keywordscalcitonin / osteoporosis / osteomalacia / osteoclast / bone absorption / enzyme immunoassay / 軟骨細胞
Research Abstract

Salmon calcitonin (SCT), one of the standard peptide therapeutics for diffuse bone diseases (i.e.osteoporosis and Paget's disease), has been clinically applied by the parenteral injections. Lately the nasal application formula tends to replace the parenterals especially for chronic use in senile and postmenopausal osteoporosis, due to a lower incidence of annoying side effects (vomiting, nausea and flushing) with the ease for self-administration. Not only clinically but also experimentally, however, no direct study has existed so far about the pharmacokinetic property of nasal SCT given in the therapeutic doses, mainly due to the lack of a rliable assay method of picomolar level of SCT.In this study, it was attempted to develop assay methods to measure SCT with highly sensitivity to determine the bioavailability of the nasal SCT.
1. Development of highly sensitive assay of SCT based on the physiological activity. (1) Cell suspensions containing osteoclasts were prepared from long bones of neonatal rats and (2) seeded onto the devitalized slices (100 mum in thickness) of bovine femur, (3) under the scanning electron microscopy and light microscopy to measure the numbers and areas of excavated lacunae (pits) and finally to evaluate the inhibitory effect of SCT on the pit formation. The detection limit of SCT achieved was less than 1 pM.
2. A highly sensitive non-competitive enzyme immunoassay method (hetero-two-site enzyme immunoassay) for SCT has been developed.
3. The application of the hetero-two-site enzyme immunoassay has enable us to directly estimate the bioavailability of nasal SCT at therapeutic levels in rats.
4. Highly sensitive and less-time consuming enzyme immunoassay (immune complex transfer two-site enzyme immunoassay) for SCT has been developed.
5. In preliminary experiments, the immune complex transfer two-site enzyme immunoassay has been applicable to measure SCT concentration in serum after intranasal administration of SCT to human.

Report

(3 results)
  • 1995 Annual Research Report   Final Research Report Summary
  • 1994 Annual Research Report
  • Research Products

    (11 results)

All Other

All Publications (11 results)

  • [Publications] Ichikawa M.,Nakamuta H.,Hoshino T.,Ogawa Y.,Koida M.: "Anti-osteopenic effect of nasal salmon calcitonin in Typel osteoporotic rats : comparison with subcutaneous dosing" Biol. Pharm. Bull.17. 911-913 (1994)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1995 Final Research Report Summary
  • [Publications] Ichikawa M.,Wanaka M.,Ohthuji T.,Akashi S.,Mochidera M.,Manno K.,Nakamuta H.,Koida M.: "Antihyperteusive effect of novel calciumantogonist,semotiadil tumarate(SD-3211) a lone and in combination with eualapril ortrichlor methiagide in sponta raonsly by pertensiverats." Biol. Pharm. Bull.17. 1513-1515 (1994)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1995 Final Research Report Summary
  • [Publications] Nitta T.,Hoshino T., Koida M.,Nakamuta H.: "Histomorphometrical evaluation of anti-ostoopenic effect of nasal salmon calcitonin ina typel osteoporotic models otrats." Biol. Pharm. Bull.19. 214-216 (1996)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1995 Final Research Report Summary
  • [Publications] Nakamuta H.,Nitta T.,Hoshino T.,Koida M.: "Glucocorticoid-induced osteopemia in rats : histomorphometricol and microarchitectual characterigation and calcitonin effect" Biol. Pharm. Bull.19. 217-219 (1996)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1995 Final Research Report Summary
  • [Publications] Kohuo T.,Nakamuta H.,Ichikawa M.,Watabe K.,Koida M.: "A noncompetitive snzyme immunoassay (hatero-two-site enzyme jmmunoassay) for salmon calcitonin : determination of bioavailability of sabcutaneous salmon calcitoin and its correlation with hypocalcemic activity in rats" J. Clin. Lab. Anal. in press.

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1995 Final Research Report Summary
  • [Publications] Nakamuta H.,Kohno T.,Ichikawa M.,Hoshino T.,Watabe K.,Koida M.: "Bioavailability of intranasal salmon calcitonin" (in preparation).

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1995 Final Research Report Summary
  • [Publications] Ichikawa M., Wanaka M., Ohthuji T., Akashi S., Machidera M., Manno K., Nakamata H., Koida M.: "Antihypertensive effrct of novel calcium antagonist, semotiadil fumarate(SD・3211) alone and in combination with enalapril or trichlormethiazide in spon taneously hyper tensive rats" Biol. Pharm. Bull.17. 1513-1515 (1994)

    • Related Report
      1995 Annual Research Report
  • [Publications] Nitta T., Hoshino T., Koida M., Nakamuta H.: "Histomorphometrical evaluation of anti-osteopenic effect of nasal salmon calcitonin in a type l osteoporotic models of rats" Biol. Pharm. Bull.19. 214-216 (1996)

    • Related Report
      1995 Annual Research Report
  • [Publications] Nakamuta H., Nitta T., Hoshino T., Koida M.: "Glucocorticoid-induced osteopenia in rats: histom orphometrical and microarchitectual characterization and calcitonin effect" Biol. Pharm. Bull.19. 217-219 (1996)

    • Related Report
      1995 Annual Research Report
  • [Publications] Kohno T., Nakamuta H., Ichikawa M., Watabe K., Koida M.: "A noncompetitive enzyme immunoassay (hotero・two・siteenzyme immunoassay)for salmon calcitomin: determination of the bioavailability of subcutaneous salmon clcaitonin and its correlation with hypocalcemin" J.Clin. Lab. Anal.(in press).

    • Related Report
      1995 Annual Research Report
  • [Publications] Ichikawa M.,Nakamuta H.,Hoshiro T.,Ogawa Y.and Koida M.: "Arti-Osteopenic Effa ct of Nasal Salmon Cal citonin Type 1 Osteoporotic Rats:Compavison with Subcutaneous Dosing" Biological & Pharmaceutical Bull otin. 17. 911-913 (1994)

    • Related Report
      1994 Annual Research Report

URL: 

Published: 1995-04-01   Modified: 2016-04-21  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi